| Literature DB >> 29551465 |
Abstract
Primary central nervous system lymphoma (PCNSL) is a rare and aggressive brain tumor. The prognosis is poor, with high rates of relapse and disease progression after treatment. In addition, PCNSL affects a largely older population, so that a significant proportion of patients are ineligible for intensive therapies and high-dose chemotherapy. The elderly patients are also susceptible to the accelerated and detrimental cognitive side effects of whole-brain irradiation which is an alternative consolidation to high-dose chemotherapy. Maintenance therapy has been shown to be a promising strategy to prolong remission time in other hematopoietic malignancies. Herein, we discuss the place of maintenance treatment in PCNSL in view of perspective obtained from hematological malignancies and non-Hodgkin's lymphoma.Entities:
Keywords: CNS lymphoma; Immune modulating therapy; Maintenance treatment; Metronomic therapy; Primary CNS lymphoma; Targeted therapy
Mesh:
Year: 2018 PMID: 29551465 DOI: 10.1016/j.blre.2018.03.003
Source DB: PubMed Journal: Blood Rev ISSN: 0268-960X Impact factor: 8.250